Loading…
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $170M | $-133M | $-194M | $-126M | -188.7% | 104.5% | - |
| 2024 | $83M | $-198M | $-227M | $-176M | -87.5% | -7.7% | - |
| 2023 | $90M | $-239M | $-263M | $-228M | -84.5% | -19.9% | - |
| 2022 | $113M | $-244M | $-280M | $-238M | -54.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 112.72 | 90.24 | 83.33 | 170.44 |
| Cost Of Revenue | 54.55 | 37.21 | 33.57 | 20.30 |
| Gross Profit | 58.18 | 53.03 | 49.76 | 150.14 |
| Operating Expense | 321.06 | 321.16 | 281.01 | 311.34 |
| Operating Income | -262.88 | -268.13 | -231.25 | -161.20 |
| EBITDA | -244.24 | -239.46 | -198.23 | -133.25 |
| EBIT | -257.15 | -256.78 | -214.44 | -148.87 |
| Pretax Income | -280.40 | -263.65 | -227.10 | -193.88 |
| Tax Provision | -0.08 | -0.15 | 0 | 0 |
| Net Income | -280.32 | -263.49 | -227.10 | -193.88 |
| Net Income Common Stockholders | -280.32 | -263.49 | -227.10 | -193.88 |
| Total Expenses | 375.60 | 358.37 | 314.57 | 331.64 |
| Interest Expense | 23.25 | 6.86 | 12.66 | 45.01 |
| Interest Income | 0.34 | 0.03 | 0.17 | 0.08 |
| Research And Development | 242.45 | 232.27 | 208.52 | 228.30 |
| Selling General And Administration | 85.28 | 88.49 | 76.62 | 82.86 |
| Normalized EBITDA | -249.62 | -250.78 | -214.86 | -145.50 |
| Normalized Income | -285.70 | -274.81 | -243.73 | -206.12 |
| Basic EPS | -6.50 | -6.02 | -4.59 | 0 |
| Diluted EPS | -6.50 | -6.02 | -4.59 | 0 |
| Tax Effect Of Unusual Items | 0 | 0.01 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 5.38 | 11.32 | 16.63 | 12.24 |
| Total Unusual Items Excluding Goodwill | 5.38 | 11.32 | 16.63 | 12.24 |
| Net Income From Continuing Operation Net Minority Interest | -280.32 | -263.49 | -227.10 | -193.88 |
| Reconciled Depreciation | 12.91 | 17.32 | 16.21 | 15.62 |
| Reconciled Cost Of Revenue | 54.55 | 37.21 | 33.57 | 20.30 |
| Net Interest Income | -22.91 | -6.84 | -12.48 | -44.92 |
| Net Income From Continuing And Discontinued Operation | -280.32 | -263.49 | -227.10 | -193.88 |
| Total Operating Income As Reported | -262.88 | -268.13 | -233.35 | -161.20 |
| Diluted Average Shares | 43.15 | 43.73 | 49.51 | 0 |
| Basic Average Shares | 43.15 | 43.73 | 49.51 | 0 |
| Diluted NI Availto Com Stockholders | -280.32 | -263.49 | -227.10 | -193.88 |
| Net Income Including Noncontrolling Interests | -280.32 | -263.49 | -227.10 | -193.88 |
| Net Income Continuous Operations | -280.32 | -263.49 | -227.10 | -193.88 |
| Other Income Expense | 5.38 | 11.32 | 16.63 | 12.24 |
| Special Income Charges | 0 | 0 | -2.10 | 0 |
| Impairment Of Capital Assets | 0 | 0 | 2.10 | 0 |
| Gain On Sale Of Security | 5.38 | 11.32 | 18.73 | 12.24 |
| Net Non Operating Interest Income Expense | -22.91 | -6.84 | -12.48 | -44.92 |
| Interest Expense Non Operating | 23.25 | 6.86 | 12.66 | 45.01 |
| Interest Income Non Operating | 0.34 | 0.03 | 0.17 | 0.08 |
| Other Operating Expenses | -6.68 | 0.40 | 0.86 | 0.18 |
| Provision For Doubtful Accounts | 0 | 0 | -5 | 0 |
| General And Administrative Expense | 85.28 | 88.49 | 76.62 | 82.86 |
| Other Gand A | 85.28 | 88.49 | 76.62 | 82.86 |
| Operating Revenue | 112.72 | 90.24 | 83.33 | 170.44 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| REGENXBIO Inc.this co. | RGNX | $434M | - | 4.16 | -188.7% | -3.19 |
| Myriad Genetics, Inc. | MYGN | $442M | - | 1.19 | -99.4% | -2.56 |
| Beta Bionics, Inc. | BBNX | $441M | - | 1.63 | -25.5% | -3.29 |
| AngioDynamics, Inc. | ANGO | $440M | - | 2.56 | -18.6% | -634.17 |
| Atea Pharmaceuticals, Inc. | AVIR | $435M | - | 1.54 |
| -57.5% |
| -0.73 |
| Evolent Health, Inc. | EVH | $432M | - | 1.02 | -128.7% | 14.29 |
| Aura Biosciences, Inc. | AURA | $432M | - | 3.13 | -77.6% | -2.73 |
| Fulgent Genetics, Inc. | FLGT | $427M | - | 0.41 | -5.5% | -1.98 |
| Vanda Pharmaceuticals Inc. | VNDA | $424M | - | 1.27 | -67.4% | -1.16 |
| Peer Median | - | - | 1.41 | -62.4% | -2.27 | |